What are the Clinical Implications of Targeting the MAPK Pathway?
Targeting the MAPK pathway has shown promise in cancer therapy. BRAF inhibitors like vemurafenib and dabrafenib have been effective in treating BRAF-mutant melanoma. However, resistance often develops through reactivation of the pathway or activation of alternative pathways, necessitating combination therapies or new strategies to overcome resistance.
